From WikiMD's free health, diet & wellness encyclopedia
Jump to navigation Jump to search

Information about Vemurafenib

Vemurafenib is a selective inhibitor of BRAF kinase that is used in the therapy of patients with metastatic and advanced malignant melanoma

Liver safety of Vemurafenib

Vemurafenib therapy is commonly associated with transient elevations in serum aminotransferase during therapy and has been linked to rare, but occasionally severe cases of clinically apparent acute liver injury

Mechanism of action of Vemurafenib

Vemurafenib (vem’ ue raf” e nib) is an orally available inhibitor of mutated forms of BRAF, a serine/threonine kinase that is a component of the mitogen-activated pathway (MAP) kinases which are important intracellular signals involved in control of cell growth and proliferation.  BRAF kinase is an early step in the cascade of MAP kinases (RAS-RAF-MEK-ERK) and is frequently mutated in malignant conditions, including at least half of cases of melanoma.  Vemurafenib was shown to be active against the V600E mutants of BRAF in vitro and in animal models.  Furthermore, in clinical trials vemurafenib therapy was associated with an improvement in overall survival in patients with metastatic malignant melanoma with V600E mutations. 

FDA approval information for Vemurafenib

Vemurafenib was approved for use in the United States in 2011 and current indications are for unresectable or metastatic melanoma with the BRAF V600E mutation and Langerhans-cell histiocytosis with BRAF V600 mutations. 

Dosage and administration for Vemurafenib

Vemurafenib is available in tablets of 240 mg under the brand name Zelboraf.  The typical dose is 960 mg (4 tablets) twice daily. 

Side effects of Vemurafenib

Common side effects include fatigue, nausea, arthralgias, rash, alopecia, photosensitivity, pruritus, and skin papilloma.  Uncommon, but potentially severe side effects include severe skin and hypersensitivity reactions (including Stevens Johnson syndrome), cutaneous squamous cell carcinoma, ocular toxicity, and prolonged QTc intervals.    Alphabetic list of antineoplastic agents - 0-9 - A1 - A2 - A3 - A4 - A5 -A6 - B - C - D - E - F - G - H - I - JK - L - M - NO - PQ - R - S - T - UVW - XYZ


Cost and Coupons - Vemurafenib

Reviews for Vemurafenib

Learn more about Vemurafenib

Latest research - Vemurafenib

Clinical trials

External links

Medicine icon
Medicine icon

This WikiMD article Vemurafenib is a stub. If you are familiar with the topic Vemurafenib, you can help us. Paid editors welcome!


Vemurafenib is part of WikiMD's free ^articles!

^Vemurafenib (article) is provided for informational purposes only. No expressed or implied warranties as to the validity of content.
WikiMD is not a substitute for professional advice. By accessing and using WikiMD you agree to the terms of use.
Templates etc. when imported from Wikipedia, are licensed under CC BY-SA 3.0. See full disclaimers.
W8MD weight loss logo

Ad. Tired of being overweight?. W8MD's physician weight loss program can HELP. Tele medicine available